Updates in Medicine Mazdutide (GLP 1 Glucagon Agonist) Cuts Weight by 14% in Obesity Trial Original Article in Bio GLORY 1 Phase 3 Trial (China, N=610) Instagram GLP 1 receptor agonists and next generation incretin based medications: metabolic, cardiovascular, and renal benefits The Lancet GLP 1s effectiveness at blood pressure control on par with traditional anti hypertensives, tracks well with % weight loss. In someone with hypertension due to their underlying obesity, why not Michael Weintraub, MD Mazdutide (IBI362): The Next Generation Dual GLP 1 Glucagon Agonist for Obesity and Metabolic Health Incretin based therapies for the treatment of obesity related diseases npj Metabolic Health and Disease Mazdutide More Biotechnology